PBYI · Puma Biotechnology, Inc.
Market Cap
$495.55M
Shares
51.62M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.59
Open$9.66
Day$9.51–9.75
52W close$4.46–9.69
Avg vol 30d292K
Short int4.3M · 8.3% float · 15.6d
Short vol53%
Last earningsAug 6, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 6 wks
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$231.24M
Trailing 12 months
Net income (TTM)
$26.72M
Trailing 12 months
Revenue growth YoY
+7.8%
Year over year
Operating margin
13.2%
Trailing 12 months
P / E (TTM)
18.4
Trailing earnings · reciprocal yield 5.4%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$93.90M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.9%
Year over year · more shares
Price change (1Y)
+117.0%
Trailing year
Short interest
8.3%
Latest settlement · 15.6 days to cover
AI Brief
Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26
TL;DR. Puma raised full-year 2026 NERLYNX net product revenue guidance to $205–$209M (from $202–$206M) and net income guidance to $17–$20M (from $16–$19M), but cut royalty guidance to $19–$22M from $20–$23M. Q2 product revenue rose to $53.6M from $49.2M a year ago, though new prescriptions fell 6% sequentially and the company is now debt-free after a final $11.1M loan payment.
Bullish
- + Raised full-year 2026 NERLYNX net product revenue guidance to $205–$209M from prior $202–$206M.
- + Raised full-year 2026 net income guidance to $17–$20M from prior $16–$19M.
- + Q2 2026 NERLYNX net product revenue rose to $53.6M from $49.2M in Q2 2025, with ex-factory bottles up 26% sequentially and 12% year-over-year.
- + Puma is now debt-free after paying off its 2021 Note Purchase Agreement, with $93.9M in cash and securities at quarter-end.
- + Alisertib ALISCA-Breast1 trial amended to focus on 40mg and 50mg dose groups, with updated interim data expected in Q4 2026.
Bearish
- − Lowered full-year 2026 royalty guidance to $19–$22M from prior $20–$23M, with potential China generic threshold triggering further rate reduction in late 2026 or 2027.
- − Q2 commercial new patient starts declined approximately 6% sequentially.
- − Q2 gross-to-net adjustment widened to 27.9% from 27% in Q1 2026, driven by higher Medicaid share.
- − R&D expenses rose to $18.9M in Q2 from $15.5M a year ago, with full-year R&D expected to grow 34%–37% year-over-year.
- − Tax asset valuation allowance remains under review and could result in a future adjustment to net income.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+32%
above
Price vs 50-day avg
+9%
above
RSI (14)
61
neutral
MACD trend
Negative
52-week position
98%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+4%
trailing
6-month return
+56%
trailing
YTD return
+61%
this year
Relative strength
+34%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +21 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.28% of float · ▲ +2.6% MoM · 15.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
161 holders — near 3-yr high, broad support
Squeeze score
70
elevated · 0–100
Fundamentals
EPS growth
−2%
Y/Y
Free cash flow
$41.7M
Valuation
P/E 18.5
rich
Balance sheet
$7.1M
net cash
Quant / Vol
risk profile
Volatility
59%
annualized · 1-yr
Max drawdown
−26%
past year
ATR
3.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Third Quarter 2026
Net Product Revenue
Initiated
$54M – $56M
Royalty Revenue
Initiated
$2M – $3M
Total Revenue
Initiated
$56M – $59M
prior qtr $56.5M
midpoint +1.8% QoQ
Net Income
Initiated
$2M – $3.5M
Gross to Net Adjustment
Initiated
26% – 27%
New Full Year 2026
Net Product Revenue
Initiated
$205M – $209M
Royalty Revenue
Initiated
$19M – $22M
Total Revenue
Initiated
$224M – $231M
prior FY $228.37M
midpoint −0.4% Y/Y
Net Income
Initiated
$17M – $20M
Gross to Net Adjustment
Initiated
26.5% – 27.5%
Prior guidance
period ended
· from the 8-K filed May 2, 2024
Royalty Revenue
· Second Quarter 2024
$2.5M – $3M
License Revenue
· Second Quarter 2024
$0
Gross to Net Adjustment
· Second Quarter 2024
22% – 23%
Net Product Revenue
· Full Year 2024
$183M – $190M
Royalty Revenue
· Full Year 2024
$30M – $33M
License Revenue
· Full Year 2024
$1M – $2M
Net Income/(Loss)
· Full Year 2024
$12M – $15M
Gross to Net Adjustment
· Full Year 2024
21.5% – 22.5%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+32%
Bullish
Price vs 50-day avg
+9%
Bullish
RSI (14)
61
Neutral
MACD trend
Negative
Bearish
52-week position
98%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $9 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +21 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.28% of float · ▲ +2.6% MoM · 15.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
161 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $10 · 98%
Range high $10
vs 200-day avg +32%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PBYI
this stock
Puma Biotechnology, Inc.
|
$495.55M | +61.2% | -0.9% | 18.5 | 8.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.84B | +12.7% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.80B | +3.4% | +20.8% | 19.4 | 2.5% |
|
MRNA
Moderna, Inc.
|
$61.50B | +486.4% | +4.3% | — | 9.8% |
|
ARGX
Argenx SE
|
$60.93B | +17.5% | — | — | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PBYI | +4.9% | +3.8% | +56.4% | +5.3% | +61.2% |
| SPY | +1.7% | +1.0% | +22.4% | +0.8% | +13.4% |
| vs SPY | +3.3% | +2.8% | +34.0% | +4.4% | +47.8% |